Drug-induced acute pancreatitis: results from the hospital-based Berlin case-control surveillance study of 102 cases.

Abstract:

BACKGROUND:Drug toxicity is a well-known cause of acute pancreatitis (AP). Although many drugs have been associated with AP, the magnitude of the risk of most of them remains largely unknown. AIM:To determine the pancreatotoxic risk of a wide range of drugs. METHODS:The hospital-based Berlin case-control surveillance study, including all 51 Berlin hospitals in a hospital network, ascertained 102 cases with idiopathic AP (IAP) and 750 controls between 2002 and 2011. Patients with IAP were thoroughly validated using anamnestic, clinical or laboratory data. Drug exposure was obtained in a face-to-face interview. Possible drug aetiology was assessed in individual patients through a standardised causality assessment applying the criteria of the World Health Organization. Drug risks were further quantified [odds ratios (OR) with 95% confidence intervals (CI)] in a case-control design with unconditional logistic regression analysis. RESULTS:The pancreatotoxic risk of several drugs, including azathioprine (OR 5.1; 95% CI 1.9-13.5), fenofibrate (OR 12.2; 95% CI 2.3-69.1), mesalazine (OR 3.3; 95% CI 1.1-9.5) or angiotensin-converting enzyme inhibitors, was corroborated by case-control analysis and causality assessment. Causality assessment suggested a pancreatotoxic potential, among others, for mercaptopurine or the seldom reported leflunomide, and alluded to a novel risk for tocilizumab. Case-control analysis showed an increased risk for two phytotherapeutics: harpagophytum and valerian radix. CONCLUSIONS:Our study quantified the pancreatotoxic risk of different drugs and phytotherapeutics. The findings corroborate previous results from the literature but also indicate risks for substances not previously reported, highlighting the need for further controlled studies on pancreatic toxicity.

journal_name

Aliment Pharmacol Ther

authors

Douros A,Bronder E,Andersohn F,Klimpel A,Thomae M,Ockenga J,Kreutz R,Garbe E

doi

10.1111/apt.12461

subject

Has Abstract

pub_date

2013-10-01 00:00:00

pages

825-34

issue

7

eissn

0269-2813

issn

1365-2036

journal_volume

38

pub_type

杂志文章
  • A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients.

    abstract:BACKGROUND:Treatment options for non-alcoholic steatohepatitis (NASH) are limited. Weight loss remains the most recommended therapy. Orlistat is an effective adjunct to dietary weight loss therapy. AIM:To evaluate the efficacy of orlistat, given for 6 months to patients with obesity and biopsy confirmed NASH. METHODS...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2004.02153.x

    authors: Harrison SA,Fincke C,Helinski D,Torgerson S,Hayashi P

    更新日期:2004-09-15 00:00:00

  • Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection.

    abstract:BACKGROUND:Functional dyspepsia is a problem that is difficult to treat in clinical practice. AIM:To evaluate the efficacy and safety of rebamipide (a cytoprotective drug) in functional dyspepsia. METHODS:Patients with functional dyspepsia (n=557) were divided a priori into two studies by Helicobacter pylori status, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.2001.01074.x

    authors: Talley NJ,Riff DS,Schwartz H,Marcuard SP

    更新日期:2001-10-01 00:00:00

  • The treatment of irritable bowel syndrome.

    abstract::The efforts of clinical researchers, lay organizations and pharmaceutical companies have increased the public profile of irritable bowel syndrome and made it a respectable diagnosis. Diagnostic symptom criteria encourage a firm clinical diagnosis, which is the foundation of a logical management strategy. This begins w...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2002.01312.x

    authors: Thompson WG

    更新日期:2002-08-01 00:00:00

  • Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation - implications for maternal dosing, foetal exposure, and safety for mother and child.

    abstract:BACKGROUND:With the global efforts to eradicate hepatitis C virus (HCV), treatment during pregnancy is becoming a priority for research as this, and maternal cure should reduce vertical transmission. However, as information on the efficacy and safety of direct-acting antivirals (DAAs) in pregnancy is generally lacking,...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15476

    authors: Freriksen JJM,van Seyen M,Judd A,Gibb DM,Collins IJ,Greupink R,Russel FGM,Drenth JPH,Colbers A,Burger DM

    更新日期:2019-10-01 00:00:00

  • Meta-analysis: Lactobacillus GG for treating acute gastroenteritis in children--updated analysis of randomised controlled trials.

    abstract:BACKGROUND:The efficacy of each probiotic should be evaluated separately. Previously, we have shown that Lactobacillus GG (LGG) is effective in treating acute gastroenteritis (AGE) in children. AIM:To update our 2007 meta-analysis on the effectiveness of LGG in treating AGE in children. METHODS:The Cochrane Library, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.12403

    authors: Szajewska H,Skórka A,Ruszczyński M,Gieruszczak-Białek D

    更新日期:2013-09-01 00:00:00

  • Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori.

    abstract:AIM:To identify optimal antibiotics for second-line quadruple therapy of Helicobacter pylori after failed 1-week triple therapy. METHODS:One hundred patients were enrolled in this study after the failure of 1-week triple therapy. They were randomized to receive 1-week quadruple therapy consisting of amoxicillin, omepr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01653.x

    authors: Chi CH,Lin CY,Sheu BS,Yang HB,Huang AH,Wu JJ

    更新日期:2003-08-01 00:00:00

  • Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer.

    abstract:BACKGROUND:Carcinoma of the gall-bladder is the fifth commonest gastrointestinal tract cancer and is endemic in several countries. An association of chronic typhoid carriage and carcinoma of the gall-bladder has been reported. AIM:To clarify whether chronic Salmonella typhi carrier state is associated with carcinoma o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1111/apt.12655

    authors: Nagaraja V,Eslick GD

    更新日期:2014-04-01 00:00:00

  • Comparative assessment of phenolphthalein and phenolphthalein glucuronide: is phenolphthalein glucuronide a better laxative?

    abstract:BACKGROUND:Phenolphthalein is widely used as a safe and effective laxative. After oral administration, phenolphthalein is absorbed in the small bowel and is conjugated in the liver to phenolphthalein glucuronide which passes into the colon where it is deconjugated and the active compound, phenolphthalein, is released. ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1994.tb00331.x

    authors: Anand BS,Torres E,Operkun A,Graham DY

    更新日期:1994-10-01 00:00:00

  • Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors.

    abstract:BACKGROUND:Several measures have been used to assess the health-related quality of life (HRQoL) of patients with eosinophilic oesophagitis (EoE). AIMS:To systematically review these HRQoL measures, to appraise measurement properties of specific instruments and to evaluate determinant factors influencing HRQoL in paedi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.14194

    authors: Lucendo AJ,Arias-González L,Molina-Infante J,Arias Á

    更新日期:2017-08-01 00:00:00

  • Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.

    abstract:BACKGROUND:The therapeutic efficacy of 5-aminosalicylic acid in inflammatory bowel disease may be related to its antioxidant properties. AIM:To compare in vitro the antioxidant effects of conventional drugs (5-aminosalicylic acid, corticosteroids, metronidazole), with new aminosalicylates (4-aminosalicylic acid, balsa...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00484.x

    authors: Simmonds NJ,Millar AD,Blake DR,Rampton DS

    更新日期:1999-03-01 00:00:00

  • Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.

    abstract:BACKGROUND:Limited data are available on the efficacy and safety of antiviral therapy in geriatric patients with chronic hepatitis C virus (HCV) infection. AIM:To evaluate the efficacy and safety of pegylated interferon (pegIFN) plus ribavirin (RBV) therapy in geriatric HCV-infected patients. METHODS:Ninety-one geria...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12112

    authors: Hu CC,Lin CL,Kuo YL,Chien CH,Chen SW,Yen CL,Lin CY,Chien RN

    更新日期:2013-01-01 00:00:00

  • A comparison between enprostil and ranitidine in the management of gastric ulceration.

    abstract::In a randomly allocated, double-blind, endoscopically controlled study, 98 patients with gastric ulcers were treated with either (a synthetic prostaglandin of E2-like structure) enprostil 70 micrograms b.d. or 150 mg ranitidine b.d. The healing rates at 4, 8 and 12 weeks were enprostil 57, 91 and 94% and for ranitidin...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1990.tb00511.x

    authors: Morgan AG,Pacsoo C,Taylor P,McAdam WA

    更新日期:1990-12-01 00:00:00

  • The effects of paracetamol (acetaminophen) on hepatic tests in patients who chronically abuse alcohol - a randomized study.

    abstract:BACKGROUND:Retrospective accounts suggest that therapeutic doses of paracetamol can produce severe hepatic injury in patients with putative high-risk conditions, including alcoholism and infectious hepatitis. Metabolism of paracetamol to its hepatotoxic metabolite is enhanced in patients who abuse alcohol, who also hav...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2010.04364.x

    authors: Dart RC,Green JL,Kuffner EK,Heard K,Sproule B,Brands B

    更新日期:2010-08-01 00:00:00

  • Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease.

    abstract:BACKGROUND:Little data are available regarding the effectiveness and associated microbiome changes of faecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in children, especially in those with inflammatory bowel disease (IBD) with presumed underlying dysbiosis. AIM:To investigate C. diffic...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13326

    authors: Hourigan SK,Chen LA,Grigoryan Z,Laroche G,Weidner M,Sears CL,Oliva-Hemker M

    更新日期:2015-09-01 00:00:00

  • Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection.

    abstract:AIM:To compare, in a randomized controlled trial, the efficacy and tolerability of two 1-week triple therapies for Helicobacter pylori eradication. METHODS:One hundred and thirty-four consecutive patients with non-ulcer dyspepsia and H. pylori infection were randomized to receive lansoprazole 30 mg once daily, clarith...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01141.x

    authors: Bazzoli F,Zagari RM,Pozzato P,Fossi S,Ricciardiello L,Nicolini G,De Luca L,Berretti D,Alampi G,Di Pietro C,Morelli P,Roda E

    更新日期:2002-01-01 00:00:00

  • Review article: inflammatory bowel disease--empowering the patient and improving outcome.

    abstract::Inflammatory bowel disease, in common with most chronic diseases, is managed by specialist clinicians during regular clinic follow-up visits. Patients spend approximately 1 h per year with clinicians, with few provisions made for patient participation in their own management for the remainder of the year, resulting in...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02061.x

    authors: Robinson A

    更新日期:2004-10-01 00:00:00

  • Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.

    abstract:BACKGROUND:The duration of Helicobacter pylori eradication regimens has decreased to 1 week with cure rates of over 90%. This can be attributed to the use of triple drug regimens including potent inhibitors of gastric acid secretion and clarithromycin. There is no theoretical reason why shorter regimens should not be p...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.1999.00574.x

    authors: Grimley CE,Penny A,O'sullivan M,Shebani M,Lismore JR,Cross R,Illing RC,Loft DE,Nwokolo CU

    更新日期:1999-07-01 00:00:00

  • Gastrimmune-induced antigastrin-17 antibodies inhibit acid secretion in a rat fistula model.

    abstract:BACKGROUND:Gastrimmune is an immunogenic form of gastrin. It raises in situ antibodies against two proliferative forms of gastrin: amidated and glycine-extended gastrin-17. It has been shown to have a therapeutic action in several in vivo tumour models. Following immunization, due to the complex equilibrium that exists...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2001.01081.x

    authors: Smith AM,Morris T,Justin T,Michaeli D,Watson SA

    更新日期:2001-12-01 00:00:00

  • Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.

    abstract:BACKGROUND:The widespread use of eradication therapy for Helicobacter pylori in Japan has led to an increase in antibiotic-resistant strains and the problem of re-treatment in cases of eradication failure. AIM:To perform drug sensitivity testing for metronidazole in 92 H. pylori-positive patients who had failed eradic...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01401.x

    authors: Murakami K,Sato R,Okimoto T,Nasu M,Fujioka T,Kodama M,Kagawa J

    更新日期:2003-01-01 00:00:00

  • Effect of omeprazole on lower oesophageal function in normal subjects.

    abstract::In a double-blind crossover study, lower oesophageal sphincter pressure (LOSP) and distal oesophageal motility were studied in eight healthy volunteers following a single intravenous dose of omeprazole or placebo. Lower oesophageal sphincter pressure was determined before and at intervals up to 120 min after intraveno...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.1987.tb00648.x

    authors: Chakraborty TK,De Caestecker JS,Pryde A,Heading RC

    更新日期:1987-12-01 00:00:00

  • Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.

    abstract:AIM:To determine whether 4 days of quadruple therapy using bismuth, tetracycline and metronidazole combined with omeprazole is effective treatment for Helicobacter pylori infection. METHODS:Non-ulcer dyspepsia, as well as chronic peptic ulcer patients with biopsy-proven H. pylori infection received 4 days of quadruple...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1111/j.1365-2036.1995.tb00432.x

    authors: De Boer WA,Driessen WM,Tytgat GN

    更新日期:1995-12-01 00:00:00

  • Relationship between the Fibrotest and portal hypertension in patients with liver disease.

    abstract:BACKGROUND:The best technique to estimate portal hypertension (PHT) is to measure the hepatic venous pressure gradient (HVPG), which is an invasive method. AIM:To assess the relationship between the Fibrotest (Biopredictive, Paris, France) and the presence and degree of PHT in patients with liver disease, and to deter...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2007.03378.x

    authors: Thabut D,Imbert-Bismut F,Cazals-Hatem D,Messous D,Muntenau M,Valla DC,Moreau R,Poynard T,Lebrec D

    更新日期:2007-08-01 00:00:00

  • Review article: the current treatment of non-cardiac chest pain.

    abstract:BACKGROUND:Non-cardiac chest pain is one of the most common functional gastrointestinal disorders. By recognising that gastro-oesophageal reflux disease (GERD), oesophageal dysmotility and oesophageal hypersensitivity are the main underlying mechanisms of NCCP, a more directed therapeutic approach has been developed. ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.13458

    authors: George N,Abdallah J,Maradey-Romero C,Gerson L,Fass R

    更新日期:2016-01-01 00:00:00

  • Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions.

    abstract:AIM:To appraise the tolerance and efficacy of an induction of tolerance protocol to infliximab permitting the re-administration of the drug to patients with Crohn's disease having had infusion reactions requiring suspension of treatment. METHODS:Fourteen patients were included in the induction of tolerance protocol. E...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03026.x

    authors: Duburque C,Lelong J,Iacob R,Seddik M,Desreumaux P,Fournier C,Wallaert B,Cortot A,Colombel JF

    更新日期:2006-09-01 00:00:00

  • An analysis of the placebo effect in Crohn's disease over time.

    abstract:BACKGROUND:Randomized, placebo controlled trials are used to assess the efficacy of therapies for Crohn's disease. The placebo response and remission rates vary among studies. AIM:To analyse how the placebo response and remission rates in Crohn's trials have changed over time in the era of parenteral biologic therapie...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2009.04125.x

    authors: Gallahan WC,Case D,Bloomfeld RS

    更新日期:2010-01-01 00:00:00

  • The prevalence of inflammatory sacroiliitis assessed on magnetic resonance imaging of inflammatory bowel disease: a retrospective study performed on 186 patients.

    abstract:BACKGROUND:Magnetic resonance imaging (MRI) colonography or enterography is increasingly used to assess disease activity and complications in inflammatory bowel disease (IBD). However, no study has evaluated the role of this imaging technique to assess sacroiliitis. AIM:The primary objective was to assess the prevalen...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12680

    authors: Leclerc-Jacob S,Lux G,Rat AC,Laurent V,Blum A,Chary-Valckenaere I,Peyrin-Biroulet L,Loeuille D

    更新日期:2014-05-01 00:00:00

  • Systematic review: has disease outcome in Crohn's disease changed during the last four decades?

    abstract:BACKGROUND:Disease outcome in Crohn's disease might have changed during the last four decades. Disease outcome measurement in Crohn's disease has methodological difficulties because of patient selection and lack of proper definition of diagnostic and outcome measurement criteria. AIM:To assess possible changes in dise...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2004.02123.x

    authors: Wolters FL,Russel MG,Stockbrügger RW

    更新日期:2004-09-01 00:00:00

  • Twenty-four-hour intragastric acidity in duodenal ulcer patients during dosing with placebo, and 150 mg ranitidine twice or four times daily.

    abstract::Twenty-four-hour intragastric acidity was measured in 10 patients with a past history of duodenal ulcer on the fourth day of dosing with placebo, and either 150 mg ranitidine given twice or four times daily. The order of the treatments was randomized and a double-blind design was employed. Ranitidine (150 mg) b.d. dec...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1989.tb00211.x

    authors: Howden CW,Tsai HH,Reid JL

    更新日期:1989-06-01 00:00:00

  • The effects of omeprazole and cimetidine on duodenal ulcer healing and the relief of symptoms.

    abstract::In a Swedish double-blind multicentre study, omeprazole (30 mg o.m.) was compared with the H2-receptor antagonist cimetidine (400 mg b.d.) in 152 patients. Clinical assessments and laboratory investigations were carried out at 2 and 4 weeks, and again at 6 weeks in unhealed patients. Endoscopy was performed at 2 weeks...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.1988.tb00721.x

    authors: Dahlgren S,Domellöf L,Hradsky M,Norryd C,Brunkwall J,Svensson G,Svensson JO,Karlsson J,Knutson U,Gasslander T

    更新日期:1988-12-01 00:00:00

  • Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN.

    abstract:BACKGROUND:Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease-related inflammation and immune suppression, but data are limited due to thei...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.14893

    authors: Joosse ME,Aardoom MA,Kemos P,Turner D,Wilson DC,Koletzko S,Martin-de-Carpi J,Fagerberg UL,Spray C,Tzivinikos C,Sladek M,Shaoul R,Roma-Giannikou E,Bronsky J,Serban DE,Ruemmele FM,Garnier-Lengline H,Veres G,Hojsak I,K

    更新日期:2018-09-01 00:00:00